This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Sep 20;25(27):4157-8.

doi: 10.1200/JCO.2007.12.1723. Epub 2007 Aug 13.

Ovarian cancer: is dose intensity dead?

PMID: 17698802
DOI: 10.1200/JCO.2007.12.1723

Editorial

Ovarian cancer: is dose intensity dead?

Robert F Ozols. J Clin Oncol. 2007.

. 2007 Sep 20;25(27):4157-8.

doi: 10.1200/JCO.2007.12.1723. Epub 2007 Aug 13.

Author

PMID: 17698802
DOI: 10.1200/JCO.2007.12.1723

No abstract available

PubMed Disclaimer

Comment on

Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA; AGO-Ovar/AIO; EBMT. Möbus V, et al. J Clin Oncol. 2007 Sep 20;25(27):4187-93. doi: 10.1200/JCO.2006.09.7527. Epub 2007 Aug 13. J Clin Oncol. 2007. PMID: 17698804 Clinical Trial.

Similar articles

Re: Meta-analysis comparing cisplatin total dose intensity and survival: a critical reappraisal.
Sauerbrei W, Blettner M, Schumacher M. Sauerbrei W, et al. Gynecol Oncol. 1996 Sep;62(3):427-9. Gynecol Oncol. 1996. PMID: 8830743 No abstract available.
Intraperitoneal chemotherapy in the treatment of ovarian cancer.
Kavanagh JJ. Kavanagh JJ. J Surg Oncol. 2007 Dec 1;96(7):541-2. doi: 10.1002/jso.20858. J Surg Oncol. 2007. PMID: 17654524 No abstract available.
[Initial treatment for ovarian cancer].
Suzuki M, Fujiwara H, Takei Y. Suzuki M, et al. Gan To Kagaku Ryoho. 2009 Feb;36(2):224-9. Gan To Kagaku Ryoho. 2009. PMID: 19263611 Japanese. No abstract available.
[Current topic of intraperitoneal infusions for treatment of ovarian cancer].
Fujiwara K. Fujiwara K. Gan To Kagaku Ryoho. 2008 Feb;35(2):224-227. Gan To Kagaku Ryoho. 2008. PMID: 18372511 Review. Japanese. No abstract available.
Intraperitoneal chemotherapy in ovarian cancer: an update.
Runowicz CD. Runowicz CD. Cancer J. 2008 Jan-Feb;14(1):7-9. doi: 10.1097/PPO.0b013e318163c2e0. Cancer J. 2008. PMID: 18303475 Review.

See all similar articles

Cited by

A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup.
Lancia C, Anninga JK, Sydes MR, Spitoni C, Whelan J, Hogendoorn PCW, Gelderblom H, Fiocco M. Lancia C, et al. Cancer Chemother Pharmacol. 2019 May;83(5):951-962. doi: 10.1007/s00280-019-03797-3. Epub 2019 Mar 16. Cancer Chemother Pharmacol. 2019. PMID: 30879111 Free PMC article.
Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial.
Musta E, van Geloven N, Anninga J, Gelderblom H, Fiocco M. Musta E, et al. BMJ Open. 2022 May 10;12(5):e052941. doi: 10.1136/bmjopen-2021-052941. BMJ Open. 2022. PMID: 35537786 Free PMC article. Clinical Trial.
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Konstantinopoulos PA, et al. Cancer Discov. 2015 Nov;5(11):1137-54. doi: 10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13. Cancer Discov. 2015. PMID: 26463832 Free PMC article. Review.
Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma.
Lancia C, Anninga J, Spitoni C, Sydes MR, Whelan J, Hogendoorn PCW, Gelderblom H, Fiocco M. Lancia C, et al. BMJ Open. 2019 May 30;9(5):e022980. doi: 10.1136/bmjopen-2018-022980. BMJ Open. 2019. PMID: 31152023 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information